Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2014

View Archived Issues

Pearl Therapeutics presents first clinical data for PT-010

CytRx begins phase Ib trial of aldoxorubicin and ifosfamide or mesna

biOasis advances lysosomal storage disease program

Roche characterizes novel alpha7-nAChR PAM

Collaboration leads to state-dependent Na(v)1.7 inhibitors for the treatment of pain

rAvPAL-loaded erythrocytes as enzyme replacement therapy for phenylketonuria

Cellceutix updates on i.v. brilacidin trial and submits IND for oral rinse formulation

Aurigene Discovery Technologies divulges novel BTK inhibitors

GlaxoSmithKline discloses novel RIP-1 inhibitors

Allergan presents new S1P1 receptor modulators

Merck & Co. synthesizes new Kir1.1 channel blockers

Kala Pharmaceuticals patents novel VEGFR-2 inhibitors

Meiji Seika presents a novel antifungal with improved efficacy against dermatophytes

CURx Pharmaceuticals licenses Captisol-formulated lamotrigine from Ligand Pharmaceuticals

Eli Lilly and Boehringer Ingelheim's insulin glargine biosimilar approved in E.U.

Mimetogen releases topline data from phase III dry eye study of MIM-D3

Serodus reports phase IIa data on SER-100 in patients with systolic hypertension

NIAAA to study gabapentin enacarbil for the treatment of alcohol use disorder

Transparency Life Sciences receives grant to support phase IIa trial of lisinopril in MS

First clinical results for 2B3-201 as potential new treatment for acute relapses in MS

Senesco Technologies changes name to Sevion Therapeutics

MabVax Therapeutics receives stockholder approval for name change

Dovobet ointment launched in Japan

SRI International and Nobelpharma sign licensing agreement on SR-16234 for endometriosis

FDA approves Contrave for chronic weight management

Baxter International to name biopharmaceutical entity Baxalta

FDA advisory committee recommends approval of liraglutide for obesity

Rhodiola rosea extract proves beneficial for stress-induced sexual dysfunction in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...